Logotype for Davide Campari-Milano N.V.

Davide Campari-Milano (CPR) Q1 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Davide Campari-Milano N.V.

Q1 2025 earnings summary

11 Jun, 2026

Executive summary

  • Q1 2025 saw organic net sales decline by 4.2% to €665.6 million, mainly due to Easter timing, logistics delays, and macroeconomic volatility, but April showed a strong bounce back in impacted markets; perimeter growth from acquisitions offset some declines.

  • Sell-out outperformed in most geographies, with double-digit growth in over 10 less developed markets and strong brand resilience, especially in April.

  • Strategic focus remains on long-term brand building, cost containment, portfolio streamlining, and geographic expansion, with no acquisitions planned and ongoing CapEx for production expansion.

  • The new operating model based on four Houses of Brands was implemented to drive efficiency and focus on core brands.

  • Prudent approach maintained amid tariff threats and economic uncertainty, with focus on deleverage and brand expansion.

Financial highlights

  • Net sales grew 0.3% year-over-year to €665.6 million, with organic sales down 4.2%, perimeter impact +4.3%, and FX +0.2%.

  • Adjusted EBITDA was €173.7 million (26.1% margin), down 4.1% year-over-year; adjusted EBIT was €136.1 million (20.4% margin), down 10.2% reported and 17.2% organically.

  • Group profit before tax-adjusted was €114 million, down 22.5% year-over-year.

  • Net financial debt at €2,460 million, leverage ratio at 3.4x net debt/EBITDA-adjusted, up from 3.2x at year-end 2024.

  • Gross margin was flat at 58.8% of net sales, supported by favorable COGS but offset by negative mix.

Outlook and guidance

  • Full-year 2025 guidance confirmed, but visibility remains low due to macroeconomic uncertainty and potential tariff impacts.

  • Negative EBIT impact from tariffs estimated at €25 million for 2025 (not annualized), with mitigation actions under review and not included in guidance.

  • Medium/long-term outlook targets mid- to high-single-digit organic net sales growth and EBIT margin accretion by 2027.

  • Cost containment program on track, with benefits expected from H2; SG&A to be reduced by 50bps in 2024 and 200bps by 2027.

  • A&P as a percentage of net sales expected at 17%-17.5% for the full year.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Davide Campari-Milano